vTv Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.
We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.
We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.
Location: United States, North Carolina, High Point
Employees: 51-200
Investors 2
| Date | Name | Website |
| 10.03.2024 | T1D Fund | t1dfund.or... |
| - | Horizon Te... | horizontec... |
Mentions in press and media 10
| Date | Title | Description |
| 13.03.2024 | vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update | - |
| 01.11.2023 | vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million | - |
| 07.12.2021 | vTv Therapeutics cuts 65% of employees in shakeup; Freenome bags $300M in Series D to expand multiomics platform | vTv Therapeutics has decided to chop down its workforce by almost two-thirds. The High Point, NC biotech announced Monday that it would pivot and now prioritize its lead program, the oral glucokinase activator TTP399, as... |
| 20.10.2021 | vTv Therapeutics : Announces Deepa Prasad as New President and CEO | HIGH POINT, N.C., Oct. 20, 2021 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced ... |
| 18.09.2019 | vTv Therapeutics reports additional positive PhII data; Shanghai Henlius prices $410 million IPO at bottom of range | → vTv Therapeutics — focused on the development of oral small molecule drug candidates — has unveiled additional positive data from its Phase II Simplici-T1 study in patients with type 1 diabetes (T1D). CSO Carmen Va... |
| 14.02.2018 | The search for new Alzheimer's treatments just faced another setback - here's where researchers are looking now | AP/Alastair Grant Advertisement It's been a while since we've had good news in search for new Alzheimer's drugs. On Tuesday, Merck said it was discontinuing one of its remaining trials that was looking at using the treatment in patients ver... |
| 31.01.2018 | After 18 years, will vTv Therapeutics’ Alzheimer’s drug sink or swim? | It would be the first new therapy the field has seen in 15 years, sweeping into a market projected to be worth $11.3 billion by 2021. But there’s no guarantee that the drug won’t stumble at the line. It’s high risk, high reward to say the l... |
| 16.11.2016 | Horizon Technology Finance Leads $25 Million Venture Loan Facility for vTv Therapeutics | FARMINGTON, Conn. and HIGH POINT, N.C., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Horizon Technology Finance Corporation (NASDAQ:HRZN), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| - | After 18 years, will vTv Therapeutics’ Alzheimer’s drug sink or swim? | There’s no denying that vTv Therapeutics has a lot riding on 2018. After 18 years of R&D, its lead drug, azeliragon, will either sink or swim based on two Phase 3 trials in Alzheimer’s disease (AD). The first is expected to be presented... |